1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
(
- Contribution to journal › Article
- 2018
-
Mark
Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
(
- Contribution to journal › Article
- 2017
-
Mark
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
(
- Contribution to journal › Article
- 2011
-
Mark
Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.
(
- Contribution to journal › Article
- 2010
-
Mark
Lu-177-[DOTA0,Tyr3] Octreotate Therapy in Patients With Disseminated Neuroendocrine Tumors: Analysis of Dosimetry With Impact on Future Therapeutic Strategy
(
- Contribution to journal › Article
- 2002
-
Mark
Single tumor cell uptake and dosimetry of technetium-99m Fab ' anti-CD22 in low-grade B-cell lymphoma
(
- Contribution to journal › Article